<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234740</url>
  </required_header>
  <id_info>
    <org_study_id>10134</org_study_id>
    <secondary_id>NCI-2010-01963</secondary_id>
    <nct_id>NCT01234740</nct_id>
  </id_info>
  <brief_title>Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases</brief_title>
  <official_title>BAFETINIB-P1-GBM-01: A Pilot Study Using Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Bafetinib in Patients With Recurrent Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bafetinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This clinical trial studies bafetinib in treating patients with recurrent high-grade&#xD;
      glioma or brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the neuropharmacokinetics (nPK) and systemic levels of bafetinib in patients&#xD;
      with recurrent malignant brain tumors.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To investigate the intrapatient variability of nPK parameters as assessed by intracerebral&#xD;
      microdialysis.&#xD;
&#xD;
      II. To document the toxicity of bafetinib in this cohort of patients. III. To describe the&#xD;
      response rate, progression-free survival, and overall survival in patients with malignant&#xD;
      brain tumors treated with bafetinib.&#xD;
&#xD;
      IV. To assess for the expression of Lyn and Fyn kinases and phosphorylation status in&#xD;
      pre-treatment tumor samples.&#xD;
&#xD;
      OUTLINE:Patients undergo intracerebral microdialysis during debulking craniotomy or&#xD;
      stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily&#xD;
      for 1 day. Beginning at least 2 weeks after craniotomy or 1 week after biopsy, patients&#xD;
      continue to receive oral bafetinib twice daily in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days and then every 8&#xD;
      weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area-under-the-concentration-time-curve (AUC) of bafetinib in dialysate</measure>
    <time_frame>every hour for 24 hours after first dose of bafetinib</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak concentration (Cmax) of bafetinib in dialysate</measure>
    <time_frame>every hour for 24 hours after first dose of bafetinib</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of bafetinib in plasma</measure>
    <time_frame>1, 2, 3, 4, 6, 8, and 12 hours after the first dose of bafetinib and then 1, 2, 3, 4, 6, 8, and 12 hours after the second dose of bafetinib</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of bafetinib in plasma</measure>
    <time_frame>1, 2, 3, 4, 6, 8, and 12 hours after the first dose of bafetinib and then 1, 2, 3, 4, 6, 8, and 12 hours after the second dose of bafetinib</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of adverse events associated with bafetinib in patient with recurrent malignant brain tumors</measure>
    <time_frame>30 days after last dose of bafetinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in patients with malignant brain tumors treated with bafetinib</measure>
    <time_frame>30 days after last dose of bafetinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in patients with malignant brain tumors treated with bafetinib</measure>
    <time_frame>1 year after last dose of bafetinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in patients with malignant brain tumors treated with bafetinib</measure>
    <time_frame>2 years after last dose of bafetinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment for expression of Lyn and Fyn kinases and phosphorylation status in pre-treatment tumor samples.</measure>
    <time_frame>Pre-treatment tumor samples</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Ependymoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <condition>Tumors Metastatic to Brain</condition>
  <condition>Adult Anaplastic Oligoastrocytoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily for 1 day. Beginning at least 2 weeks after surgery, patients continue to receive oral bafetinib twice daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bafetinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>dual Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406</other_name>
    <other_name>INNO-406</other_name>
    <other_name>NS-187</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>microdialysis</intervention_name>
    <description>Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid chromatography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>LC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Blotting, Western</other_name>
    <other_name>Western Blot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>debulking craniotomy</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have radiographic findings consistent with either:&#xD;
&#xD;
               -  Recurrent high-grade glioma, or&#xD;
&#xD;
               -  Metastatic disease to the brain that has progressed after treatment with whole&#xD;
                  brain radiation therapy or stereotactic radiosurgery; patients who have a&#xD;
                  resectable brain metastasis as the only site of disease (i.e., no evidence of&#xD;
                  systemic disease), are not eligible to participate&#xD;
&#xD;
          -  Patients who are in need of a surgical debulking or a stereotactic biopsy for the&#xD;
             purpose of diagnosis or differentiating between tumor progression versus&#xD;
             treatment-induced effects following radiation therapy +/- chemotherapy will be&#xD;
             eligible to participate in the microdialysis part of the study prior to beginning&#xD;
             cycle 1 of bafetinib if the study neurosurgeon thinks there is a likelihood of being&#xD;
             able to place the microdialysis catheter into residual tumor (enhancing brain tissue)&#xD;
&#xD;
          -  Patients who choose not to participate in the microdialysis part of the study may&#xD;
             enroll in the study and start treatment at cycle 1 of bafetinib&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control or abstinence) prior to study entry and&#xD;
             for 3 months following duration of study participation; should a woman become pregnant&#xD;
             or suspect that she is pregnant while participating on the trial, she should inform&#xD;
             her treating physician immediately&#xD;
&#xD;
          -  Patients must have a Karnofsky Performance Status (KPS) &gt;= 60%&#xD;
&#xD;
          -  If corticosteroids are required for controlling cerebral edema, patients must be on a&#xD;
             stable dose for at least 1 week prior to enrollment&#xD;
&#xD;
          -  Patients must not be taking any hepatic enzyme-inducing anticonvulsants (phenytoin,&#xD;
             carbamazepine, phenobarbital, primidone, oxcarbazepine) for at least 2 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1500 cells/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000 cells/mm^3&#xD;
&#xD;
          -  Total bilirubin =&lt; 2.0 mg/dl&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =&lt; 3&#xD;
             times the institutional upper limit of normal&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =&lt; 3&#xD;
             times the institutional upper limit of normal&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x the institutional upper limit of normal&#xD;
&#xD;
          -  QTc interval &lt; 480 msec on electrocardiogram (ECG)&#xD;
&#xD;
          -  All subjects must have the ability to understand and the willingness to sign a written&#xD;
             informed consent&#xD;
&#xD;
          -  Patients must have recovered from any toxicity of prior therapies (including brain&#xD;
             radiation); an interval of at least 6 weeks must have elapsed since the completion of&#xD;
             a nitrosourea-containing chemotherapy regimen; patients who have undergone a recent&#xD;
             craniotomy cannot begin bafetinib until at least 2 weeks after the surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are currently receiving chemotherapy or are enrolled in another treatment&#xD;
             clinical trial&#xD;
&#xD;
          -  Patients with a coagulopathy or bleeding disorder&#xD;
&#xD;
          -  Patients on anticoagulant drug therapy or medications that inhibit platelet function,&#xD;
             such as ibuprofen or other non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Clinically evident congestive heart failure &gt; class II of the New York Heart&#xD;
             Association (NYHA) guidelines&#xD;
&#xD;
          -  Clinically significant cardiac arrhythmias&#xD;
&#xD;
          -  Patients taking a drug that can prolong the QT interval; if a potential study patient&#xD;
             is taking one of the prohibited drugs but s/he can safely stop it, then a washout&#xD;
             period of &gt;= 7 days is required prior to starting bafetinib&#xD;
&#xD;
          -  History or signs of active coronary artery disease with or without angina pectoris&#xD;
&#xD;
          -  Patients who have a serious medical or psychiatric illness that could, in the&#xD;
             investigator's opinion, potentially interfere with the completion of treatment&#xD;
             according to this protocol or may not be able to comply with the safety monitoring&#xD;
             requirements of the study&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy&#xD;
             are excluded from the study due to the possibility of pharmacokinetic (PK)&#xD;
             interactions with bafetinib; however, patients will not be routinely screened for HIV&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Active, clinically significant serious infection requiring treatment with antibiotics,&#xD;
             anti-virals or anti-fungals&#xD;
&#xD;
          -  Patients who have not recovered from the toxicities of prior chemotherapy or&#xD;
             radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jana Portnow</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Pasadena Cancer Center</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Los Angeles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bafetinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

